ELI LILLY AND COMPANY Increase (Decrease) in Income Taxes Payable
ELI LILLY AND COMPANY (LLY) reported Increase (Decrease) in Income Taxes Payable of $346.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2023-02-22
- ELI LILLY AND COMPANY increase (decrease) in income taxes payable for fiscal 2022 was $346.60M.
- ELI LILLY AND COMPANY increase (decrease) in income taxes payable for fiscal 2021 was -$359.70M, a 211.71% decline from fiscal 2020.
- ELI LILLY AND COMPANY increase (decrease) in income taxes payable for fiscal 2020 was $322.00M.
- ELI LILLY AND COMPANY increase (decrease) in income taxes payable for fiscal 2019 was -$221.30M.
| Period end | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|
| 2022-12-31 | $346.60M 10-K · filed 2023-02-22 |
| 2021-12-31 | -$359.70M 10-K · filed 2023-02-22 |
| 2020-12-31 | $322.00M 10-K · filed 2023-02-22 |
| 2019-12-31 | -$221.30M 10-K · filed 2022-02-23 |
| 2018-12-31 | -$125.30M 10-K · filed 2021-02-17 |
| 2017-12-31 | $3.49B 10-K · filed 2020-02-19 |
| 2016-12-31 | -$304.80M 8-K · filed 2019-10-24 |
| 2015-12-31 | -$17.80M 10-K · filed 2018-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |